Shukui Qin

Also affiliated with China Pharmaceutical University, Beijing Tian Tan Hospital, Jiangsu Cancer Hospital

MedicineBiochemistry, Genetics and Molecular Biology

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

1in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Why this DataRank?

An author's DataRank is the sum of the DataRanks of all 1 indexed paper attributed to them. A prolific author with many moderate-impact papers can outrank one with a single high-impact paper.

Author scores recompute whenever paper DataRanks are refreshed, so this number lags the underlying paper scores by at most one batch run.

Read the full methodology →

Papers

Driven by 3 papers. Top paper: “Pembrolizumab in HER2-Positive Gastric Cancer”.

Pembrolizumab in HER2-Positive Gastric Cancer

New England Journal of Medicine(2024)10.1056/nejmc2408121

N/A

1.4DataRank · unranked

65 citations

Akihito Kawazoe, Yuxian Bai, Jianming Xu, Sara Lonardi, Jean Phillipe Metges +21 more

Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma

New England Journal of Medicine(2020)10.1056/nejmoa1915745

N/A

1.3DataRank · unranked

7029 citations

Shukui Qin, Masafumi Ikeda, Peter R. Galle, Michel Ducreux, Tae-You Kim +19 more

Randomized double-blind placebo-controlled phase 2 study of bemarituzumab combined with modified FOLFOX6 (mFOLFOX6) in first-line (1L) treatment of advanced gastric/gastroesophageal junction adenocarcinoma (FIGHT).

Journal of Clinical Oncology(2021)10.1200/jco.2021.39.3_suppl.160

N/A

0.652DataRank · unranked

76 citations

Peter C. Enzinger, Yoon-Koo Kang, Kensei Yamaguchi, Shukui Qin, Keun-Wook Lee +11 more